WHIPPANY, N.J., Aug. 20, 2015 /PRNewswire/ -- Pazoo, Inc. (OTC Pinks: PZOO) (German WKN#: A1J3DK), is pleased to report that Pazoo will hold a conference call next Wednesday, August 26, 2015, from 12:00 noon to 2:00 p.m. eastern time. Pazoo CEO, David Cunic, will be answering questions sent to the company in advance by those wishing to learn more about what is transpiring with the company. Due to time constraints, we may not be able to answer all questions submitted. Also we may be limited by the nature of the information sought. Pazoo will not disclose any non-public information, nor will it disclose any information that is subject to any confidentiality agreement or any information the disclosure of which would violate any agreement, law, rule or regulation to which the Pazoo subject. We will likely be answering questions regarding Pazoo's increasing footprint in the marijuana industry. No information provided on the conference call should be considered legal advice regarding any laws or regulations Pazoo is required to comply with in this arena. Any participant on the call should seek independent legal counsel regarding any concerns they may have in this regard.
All questions should be emailed in advance to [email protected] not later than 12:00 noon, Tuesday, August 25, 2015. Anyone not seeking to have a question answered, but wishes to listen in on the call, also needs to email [email protected] to request the dial in information. The dial in information will be provided to all who request to be on the call not later than Tuesday afternoon August 25, 2015.
Safe Harbor Statement:
This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.
ABOUT PAZOO Inc.
Pazoo, Inc., is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly-owned subsidiary, Harris Lee, and our partnership with MA & Associates, Pazoo provides industry-leading laboratory testing of cannabis. Harris Lee's and MA's license agreements with Steep Hill Labs, Inc. allows the Pazoo subsidiaries to use Steep Hill's top-rated testing protocols in select markets as we expand throughout the USA. Pazoo's subsidiaries are currently licensed to test cannabis in Nevada, Oregon and Colorado, with other states to come. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its website www.pazoo.com.
ABOUT STEEP HILL LABS Inc.
Founded in California in 2008, Steep Hill is a science and technology firm that has become the industry leader in cannabis testing and analytics. With owned and licensed labs in four U.S. states and plans to add labs in New Mexico, Oregon and possibly Jamaica in 2015, Steep Hill is the largest cannabis lab network in the world. The company pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California - the first state to legalize medical cannabis. Steep Hill has since developed a variety of revolutionary cannabis testing products, including QuantaCann™, QuantaCann2™ and GenKit™. Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services for the industry as well.
SOURCE Pazoo, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article